Drug Companies Step Forward with Voluntary Price Caps on Inhalers
The price cap will help reduce the financial burden for many people who use respiratory inhalers to treat asthma and COPD.
The price cap will help reduce the financial burden for many people who use respiratory inhalers to treat asthma and COPD.
Eczema camps are now an option for families. They offer a tailored experience for children with eczema and other skin diseases.
The FDA has approved respiratory syncytial virus (RSV) vaccines for older adults and an RSV monoclonal antibody for infants and young children.
Airline Emergency Medical Kits should include epinephrine to ensure passengers are treated for severe or life-threatening allergic reactions.
Allergy & Asthma Network urges USDA to support including peanut-containing products in infant food packages.
AAN is headed to Washington, DC to advocate for healthcare policies and legislation that promote access to care and health equity.
AAN plans to engage in at least 20 community outreach events nationwide this year – from Los Angeles to Dallas to New York City.
Asthma patients who use one of Teva’s three Digihaler devices should talk wit their doctor about alternatives.
The new EPA standards for vehicles will help protect respiratory health and address climate change.
Chronic spontaneous urticaria (CSU) can impact teens, but a new clinical trial may provide options.
Learn about a research study looking into the use of a biologic to determine if it can aid food allergy oral immunotherapy.
A new medication supports treating asthma symptoms and inflamed airways in the short and long term using one inhaler device.
End of content
End of content

10304 Eaton Place, Suite 100
Fairfax, VA 22030
Phone: 800-878-4403
Join Our Newsletter
Keep up with the latest news from Allergy & Asthma Network, right in your inbox! Choose from our E-Newsletter, Research or EXHALE newsletters.
🔐 We do not share or sell your information.